Concepedia

Jeffrey O. Saunders

JO

Statistics

Publications

13

Citations

2.8K

H-Index

13

Active since

1981

Affiliations

Agios Pharmaceuticals (United States)(Current)

Vertex Pharmaceuticals (United States)

Institut Gustave Roussy

Inserm

Schrodinger (United States)

Jeffrey O. Saunders is an author at Agios Pharmaceuticals (United States) specializing in pharmacology, enzyme inhibition, and chemistry.

Publications per year

1981–2018

13

Publications

13

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

Fang Wang, Jeremy Travins, Byron DeLaBarre et al. · Science · 2013 · 797 citations

, , +10

Discovery of Indoles as Potent and Selective Inhibitors of the Deacetylase SIRT1

Andrew D. Napper, Jeffrey Hixon, Thomas McDonagh et al. · Journal of Medicinal Chemistry · 2005 · 525 citations · Full text

, , +13

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations

Katharine Yen, Jeremy Travins, Fang Wang et al. · Cancer Discovery · 2017 · 458 citations · Full text

, , +17

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

Janeta Popovici-Müller, René M. Lemieux, Erin Artin et al. · ACS Medicinal Chemistry Letters · 2018 · 444 citations · Full text

, , +14

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG <i>in Vivo</i>

Janeta Popovici-Müller, Jeffrey O. Saunders, Francesco G. Salituro et al. · ACS Medicinal Chemistry Letters · 2012 · 197 citations · Full text

, , +6

1–5 of 13